Taiho suffers setback with DMD hopeful

Shares in Japanese drugmaker Otsuka Holdings (TYO: 4578) closed nearly 2% lower Tuesday, after disappointing clinical trial results from one of its subsidiaries.

Otsuka subsidiary Taiho Pharmaceuticals earlier announced that the results of a Phase III, randomized, placebo-controlled, double-blind and open-label, extension study of TAS-205 in patients with Duchenne muscular dystrophy (DMD) (REACH-DMD).

Data showed no significant difference in the mean change from baseline to 52 weeks in the time to rise from the floor, which was the primary endpoint in the ambulatory cohort of the study.